SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001562180-18-003988
Filing Date
2018-09-19
Accepted
2018-09-19 19:08:26
Documents
2
Period of Report
2018-09-17

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 11135
2 MARK VELLECA POA SEP 2018 mvelleca_sep2018poa.txt EX-24 3441
  Complete submission text file 0001562180-18-003988.txt   16126
Mailing Address P. O. BOX # 110341 RESEARCH TRIANGLE PARK NC 27709
Business Address 79 T.W. ALEXANDER DRIVE 4501 RESEARCH COMMONS, SUITE 100 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Issuer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 79 TW ALEXANDER DRIVE 4501 RESEARCH COMMONS, SUITE 100 RESEARCH TRIANGLE PARK NC 27709
Business Address
Velleca Mark A. (Reporting) CIK: 0001706847 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38096 | Film No.: 181078452